Transferrin receptor targeting chimeras for membrane protein degradation

  • Mayle, K. M., Le, A. M. & Kamei, D. T. The intracellular trafficking pathway of transferrin. Biochim. Biophys. Acta 1820, 264–281 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cheng, Y., Zak, O., Aisen, P., Harrison, S. C. & Walz, T. Structure of the human transferrin receptor-transferrin complex. Cell 116, 565–576 (2004).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Candelaria, P. V., Leoh, L. S., Penichet, M. L. & Daniels-Wells, T. R. Antibodies targeting the Transferrin Receptor 1 (TfR1) as direct anti-cancer agents. Front. Immunol. 12, 607692 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Iacopetta, B. J. & Morgan, E. H. The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J. Biol. Chem. 258, 9108–9115 (1983).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ciechanover, A., Schwartz, A. L., Dautry-Varsat, A. & Lodish, H. F. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J. Biol. Chem. 258, 9681–9689 (1983).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rhee, K. & Zhou, X. Two in one: the emerging concept of bifunctional antibodies. Curr. Opin. Biotechnol. 85, 103050 (2024).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wells, J. A. & Kumru, K. Extracellular targeted protein degradation: an emerging modality for drug discovery. Nat. Rev. Drug Discov. 23, 126–140 (2024).

    Article 
    PubMed 

    Google Scholar
     

  • Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B. & Wells, J. A. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143, 593–598 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Marei, H. et al. Antibody targeting of E3 ubiquitin ligases for receptor degradation. Nature https://doi.org/10.1038/s41586-022-05235-6 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gramespacher, J. A., Cotton, A. D., Burroughs, P. W. W., Seiple, I. B. & Wells, J. A. Roadmap for optimizing and broadening antibody-based PROTACs for degradation of cell surface proteins. ACS Chem. Biol. 17, 1259–1268 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Siepe, D. H., Picton, L. K. & Garcia, K. C. Receptor elimination by E3 ubiquitin ligase recruitment (REULR): a targeted protein degradation toolbox. ACS Synth. Bio. 12, 1081–1093 (2023).

    Article 
    CAS 

    Google Scholar
     

  • Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Banik, S. M. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584, 291–297 (2020).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pance, K. et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01456-2 (2022).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhou, Y., Teng, P., Montgomery, N. T., Li, X. & Tang, W. Development of triantennary N-acetylgalactosamine conjugates as degraders for extracellular proteins. ACS Cent Sci 7, 499–506 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Caianiello, D. F. et al. Bifunctional small molecules that mediate the degradation of extracellular proteins. Nat. Chem. Biol. 17, 947–953 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zheng, J. et al. Bifunctional compounds as molecular degraders for integrin-facilitated targeted protein degradation. J. Am. Chem. Soc. 144, 21831–21836 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Miao, Y. et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angew. Chem. Int. Ed. 60, 11267–11271 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Ahn, G. et al. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382, eadf6249 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shen, F. & Dassama, L. M. K. Opportunities and challenges of protein-based targeted protein degradation. Chem. Sci. 14, 8433–8447 (2023).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kawabata, H. Transferrin and transferrin receptors update. Free Radic. Biol. Med. 133, 46–54 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Daniels, T. R. et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta 1820, 291–317 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hogemann-Savellano, D. et al. The transferrin receptor: a potential molecular imaging marker for human cancer. Neoplasia 5, 495–506 (2003).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hopkins, C. R., Miller, K. & Beardmore, J. M. Receptor-mediated endocytosis of transferrin and epidermal growth factor receptors: a comparison of constitutive and ligand-induced uptake. J. Cell Sci. Suppl. 3, 173–186 (1985).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hsu, V. W., Bai, M. & Li, J. Getting active: protein sorting in endocytic recycling. Nat. Rev. Mol. Cell Biol. 13, 323–328 (2012).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Shaul, Y. D. et al. MERAV: a tool for comparing gene expression across human tissues and cell types. Nucleic Acids Res. 44, D560–D566 (2016).

    Article 
    MathSciNet 
    CAS 
    PubMed 

    Google Scholar
     

  • Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 175, 1701–1715 e1716 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Klesmith, J. R. et al. Retargeting CD19 chimeric antigen receptor T cells via engineered CD19-fusion proteins. Mol. Pharm. 16, 3544–3558 (2019).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Naqvi, S. A. et al. Insertion of a lysosomal enzyme cleavage site into the sequence of a radiolabeled neuropeptide influences cell trafficking in vitro and in vivo. Cancer Biother. Radiopharm. 25, 89–95 (2010).

    PubMed 

    Google Scholar
     

  • Poreba, M. Protease-activated prodrugs: strategies, challenges, and future directions. FEBS J. 287, 1936–1969 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Anami, Y. et al. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice. Nat. Commun. 9, 2512 (2018).

    Article 
    ADS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Goenaga, A. L. et al. Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies. Mol. Immunol. 44, 3777–3788 (2007).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tillotson, B. J., Goulatis, L. I., Parenti, I., Duxbury, E. & Shusta, E. V. Engineering an anti-transferrin receptor ScFv for pH-sensitive binding leads to increased intracellular accumulation. PLoS ONE 10, e0145820 (2015).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Santomasso, B., Bachier, C., Westin, J., Rezvani, K. & Shpall, E. J. The other side of CAR T-Cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden. Am. Soc. Clin. Oncol. Educ. Book 39, 433–444 (2019).

    Article 
    PubMed 

    Google Scholar
     

  • Brandt, L. J. B., Barnkob, M. B., Michaels, Y. S., Heiselberg, J. & Barington, T. Emerging approaches for regulation and control of CAR T cells: a mini review. Front. Immunol. 11, 326 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Herbst, R. S. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N. Engl. J. Med. 383, 1328–1339 (2020).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Friedman, M. et al. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J. Mol. Biol. 376, 1388–1402 (2008).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pierpont, T. M., Limper, C. B. & Richards, K. L. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front. Oncol. 8, 163 (2018).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Huotari, J. & Helenius, A. Endosome maturation. EMBO J. 30, 3481–3500 (2011).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fu, H., Jiang, Y., Wong, W. P. & Springer, T. A. Single-molecule imaging of von Willebrand factor reveals tension-dependent self-association. Blood 138, 2425–2434 (2021).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 19, 2240–2247 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cross, D. A. et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 4, 1046–1061 (2014).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Leonetti, A. et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br. J. Cancer 121, 725–737 (2019).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thress, K. S. et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 21, 560–562 (2015).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ercan, D. et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29, 2346–2356 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Haikala, H. M. et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res. 82, 130–141 (2022).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cho, J. et al. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 73, 6770–6779 (2013).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kurppa, K. J. et al. Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway. Cancer Cell 37, 104–122 e112 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Richard, C. & Verdier, F. Transferrin receptors in erythropoiesis. Int. J. Mol. Sci. 21, 9713 (2020).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kim, B. J. et al. Transferrin fusion technology: a novel approach to prolonging biological half-life of insulinotropic peptides. J. Pharmacol. Exp. Ther. 334, 682–692 (2010).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Su, L. Y. et al. Anti-tumor immunotherapy using engineered bacterial outer membrane vesicles fused to lysosome-targeting chimeras mediated by transferrin receptor. Cell. Chem. Biol. https://doi.org/10.1016/j.chembiol.2024.01.002 (2024).

    Article 
    PubMed 

    Google Scholar
     

  • Giovannini, M. et al. Clinical significance of skin toxicity due to EGFR-targeted therapies. J. Oncol. 2009, 849051 (2009).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pulgar, V. M. Transcytosis to cross the blood brain barrier, new advancements and challenges. Front. Neurosci. 12, 1019 (2018).

    Article 
    PubMed 

    Google Scholar
     

  • Sonoda, H. et al. A blood-brain-barrier-penetrating anti-human transferrin receptor antibody fusion protein for neuronopathic mucopolysaccharidosis II. Mol. Ther. 26, 1366–1374 (2018).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Okuyama, T. et al. A phase 2/3 trial of pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II. Mol. Ther. 29, 671–679 (2021).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Niewoehner, J. et al. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49–60 (2014).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hultqvist, G., Syvanen, S., Fang, X. T., Lannfelt, L. & Sehlin, D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics 7, 308–318 (2017).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu, R., Oldham, R. J., Teal, E., Beers, S. A. & Cragg, M. S. Fc-engineering for modulated effector functions-improving antibodies for cancer treatment. Antibodies 9, 64 (2020).

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang, X., Mathieu, M. & Brezski, R. J. IgG Fc engineering to modulate antibody effector functions. Protein Cell 9, 63–73 (2018).

  • Yamin, R. et al. Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy. Nature 599, 465–470 (2021).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Roth, T. L. et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 559, 405–409 (2018).

    Article 
    ADS 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     


  • Source link

    Total
    0
    Shares
    Leave a Reply

    Your email address will not be published. Required fields are marked *

    Related Posts